Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized Retreatment with Bortezomib in Relapsed Multiple Myeloma
NCT01910987Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2013
- Primary completion
- Feb 2016
- Modality
- Small Molecules, Modified Peptides
- Countries
- 11
01
Overview
A Phase 3 trial of bortezomib in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Apr 2013; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01910987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01910987.